Generic Name and Formulations:
Sacrosidase 8500 IU/mL; oral soln.
QOL Medical, LLC
Indications for SUCRAID:
Oral replacement therapy of the genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency.
<5months: not recommended. ≥5months: ≤15kg: 8500 IU per meal or snack. >15kg: 17000 IU per meal or snack. Dilute dose with 2–4 ounces of water, milk, or infant formula. Serve cold or at room temp; do not warm up or heat liquid before or after addition of Sucraid. Give half the dose at the beginning of the meal/snack and the remainder during meal/snack.
Hypersensitivity to yeast, glycerin, papain.
Administer initial dose near facility where acute hypersensitivity reactions can be treated; discontinue if hypersensitivity occurs. Diabetes. Evaluate for dietary starch restriction. Secondary disaccharidase deficiencies. Pregnancy (Cat. C).
Do not reconstitute or consume with fruit juice; acidity reduces enzyme activity.
Abdominal pain, GI upset, constipation, insomnia, headache, nervousness, dehydration; rare: wheezing.
Soln (118mL)—2 bottles (w. measuring scoops)
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Triiodothyronine in the Treatment of Bipolar Depression
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed
- Intranasal Oxytocin Reduces Negative Effects, Improves Cognitive Function in Schizophrenia
- E-Cigarettes Associated With More Harms Than Benefits at Population Level
- Examining Rates of Long-Term Opioid Use in Youth With Psychiatric Disorders
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Researchers Identify Novel Potential Biomarkers for Autism
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Personal Health Information Found in Recycling
- Nightmares in Military Personnel Frequently Comorbid With Mental Health Disorders
- Potential for SERMs as Adjunctive Therapy for Schizophrenia
- Addressing Racial Disparities in Bipolar Disorder Treatment
- Negative Symptoms Increase Cardiovascular Risk in Schizophrenia